ID   CEBPA_RAT               Reviewed;         358 AA.
AC   P05554;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 3.
DT   02-OCT-2024, entry version 181.
DE   RecName: Full=CCAAT/enhancer-binding protein alpha {ECO:0000312|RGD:2326};
DE            Short=C/EBP alpha;
GN   Name=Cebpa {ECO:0000312|RGD:2326};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 253-269.
RC   STRAIN=Sprague-Dawley;
RX   PubMed=2850264; DOI=10.1101/gad.2.7.786;
RA   Landschulz W.H., Johnson P.F., Adashi E.Y., Graves B.J., McKnight S.L.;
RT   "Isolation of a recombinant copy of the gene encoding C/EBP.";
RL   Genes Dev. 2:786-800(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND SEQUENCE REVISION.
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RX   PubMed=7926792; DOI=10.1101/gad.8.9.1131;
RA   Lincoln A.J., Williams S.C., Johnson P.F.;
RT   "A revised sequence of the rat c/ebp gene.";
RL   Genes Dev. 8:1131-1132(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [4]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=1884998; DOI=10.1101/gad.5.9.1553;
RA   Williams S.C., Cantwell C.A., Johnson P.F.;
RT   "A family of C/EBP-related proteins capable of forming covalently linked
RT   leucine zipper dimers in vitro.";
RL   Genes Dev. 5:1553-1567(1991).
RN   [5]
RP   SUBUNIT.
RX   PubMed=1377818; DOI=10.1093/nar/20.12.3091;
RA   Thomassin H., Hamel D., Bernier D., Guertin M., Belanger L.;
RT   "Molecular cloning of two C/EBP-related proteins that bind to the promoter
RT   and the enhancer of the alpha 1-fetoprotein gene. Further analysis of C/EBP
RT   beta and C/EBP gamma.";
RL   Nucleic Acids Res. 20:3091-3098(1992).
RN   [6]
RP   FUNCTION, ALTERNATIVE TRANSLATIONAL INITIATION, SUBCELLULAR LOCATION,
RP   DEVELOPMENTAL STAGE, TISSUE SPECIFICITY, SUBUNIT, AND DNA-BINDING.
RX   PubMed=8367486; DOI=10.1073/pnas.90.17.8219;
RA   Ossipow V., Descombes P., Schibler U.;
RT   "CCAAT/enhancer-binding protein mRNA is translated into multiple proteins
RT   with different transcription activation potentials.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:8219-8223(1993).
RN   [7]
RP   FUNCTION, AND MUTAGENESIS OF TYR-285; VAL-287; GLU-290; ILE-294; ARG-297;
RP   ASP-301 AND LYS-304.
RX   PubMed=11672531; DOI=10.1016/s0092-8674(01)00516-5;
RA   Porse B.T., Pedersen T.A., Xu X., Lindberg B., Wewer U.M., Friis-Hansen L.,
RA   Nerlov C.;
RT   "E2F repression by C/EBPalpha is required for adipogenesis and
RT   granulopoiesis in vivo.";
RL   Cell 107:247-258(2001).
RN   [8]
RP   FUNCTION, INTERACTION WITH SMARCA2, SUMOYLATION AT LYS-159, AND MUTAGENESIS
RP   OF LYS-159.
RX   PubMed=16735515; DOI=10.1074/jbc.m600852200;
RA   Sato Y., Miyake K., Kaneoka H., Iijima S.;
RT   "Sumoylation of CCAAT/enhancer-binding protein alpha and its functional
RT   roles in hepatocyte differentiation.";
RL   J. Biol. Chem. 281:21629-21639(2006).
RN   [9]
RP   ALTERNATIVE INITIATION, IDENTIFICATION OF NON-CANONICAL INITIATION CODON,
RP   SUBCELLULAR LOCATION (ISOFORM 4), MUTAGENESIS (ISOFORM 4), MUTAGENESIS OF
RP   SER-299, AND INTERACTION WITH NPM1; TAF1A AND UBTF.
RX   PubMed=20075868; DOI=10.1038/emboj.2009.404;
RA   Muller C., Bremer A., Schreiber S., Eichwald S., Calkhoven C.F.;
RT   "Nucleolar retention of a translational C/EBPalpha isoform stimulates rDNA
RT   transcription and cell size.";
RL   EMBO J. 29:897-909(2010).
RN   [10]
RP   FUNCTION, INTERACTION WITH TFDP1; TFDP2 AND E2F1, AND MUTAGENESIS OF
RP   GLU-290; ILE-294; ARG-297; ASP-301 AND LYS-304.
RX   PubMed=20176812; DOI=10.1128/mcb.01619-09;
RA   Zaragoza K., Begay V., Schuetz A., Heinemann U., Leutz A.;
RT   "Repression of transcriptional activity of C/EBPalpha by E2F-dimerization
RT   partner complexes.";
RL   Mol. Cell. Biol. 30:2293-2304(2010).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 281-340 IN COMPLEX WITH DNA,
RP   SUBUNIT, MUTAGENESIS OF TYR-285; ARG-289; ASN-293 AND VAL-296, AND
RP   SPECIFICITY.
RX   PubMed=12578822; DOI=10.1074/jbc.m300417200;
RA   Miller M., Shuman J.D., Sebastian T., Dauter Z., Johnson P.F.;
RT   "Structural basis for DNA recognition by the basic region leucine zipper
RT   transcription factor CCAAT/enhancer-binding protein alpha.";
RL   J. Biol. Chem. 278:15178-15184(2003).
CC   -!- FUNCTION: Transcription factor that coordinates proliferation arrest
CC       and the differentiation of myeloid progenitors, adipocytes,
CC       hepatocytes, and cells of the lung and the placenta (PubMed:11672531,
CC       PubMed:16735515, PubMed:20176812, PubMed:8367486). Binds directly to
CC       the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator
CC       on distinct target genes. During early embryogenesis, plays essential
CC       and redundant functions with CEBPB (By similarity). Essential for the
CC       transition from common myeloid progenitors (CMP) to
CC       granulocyte/monocyte progenitors (GMP) (PubMed:11672531). Critical for
CC       the proper development of the liver and the lung (By similarity).
CC       Necessary for terminal adipocyte differentiation, is required for
CC       postnatal maintenance of systemic energy homeostasis and lipid storage
CC       (PubMed:11672531). To regulate these different processes at the proper
CC       moment and tissue, interplays with other transcription factors and
CC       modulators. Down-regulates the expression of genes that maintain cells
CC       in an undifferentiated and proliferative state through E2F1 repression,
CC       which is critical for its ability to induce adipocyte and granulocyte
CC       terminal differentiation. Reciprocally E2F1 blocks adipocyte
CC       differentiation by binding to specific promoters and repressing CEBPA
CC       binding to its target gene promoters (PubMed:11672531). Proliferation
CC       arrest also depends on a functional binding to SWI/SNF complex (By
CC       similarity). In liver, regulates gluconeogenesis and lipogenesis
CC       through different mechanisms. To regulate gluconeogenesis, functionally
CC       cooperates with FOXO1 binding to IRE-controlled promoters and
CC       regulating the expression of target genes such as PCK1 or G6PC1. To
CC       modulate lipogenesis, interacts and transcriptionally synergizes with
CC       SREBF1 in promoter activation of specific lipogenic target genes such
CC       as ACAS2. In adipose tissue, seems to act as FOXO1 coactivator
CC       accessing to ADIPOQ promoter through FOXO1 binding sites (By
CC       similarity). {ECO:0000250|UniProtKB:P49715,
CC       ECO:0000250|UniProtKB:P53566, ECO:0000269|PubMed:11672531,
CC       ECO:0000269|PubMed:16735515, ECO:0000269|PubMed:20176812,
CC       ECO:0000269|PubMed:8367486}.
CC   -!- FUNCTION: [Isoform 3]: Can act as dominant-negative. Binds DNA and have
CC       transctivation activity, even if much less efficiently than isoform 2.
CC       Does not inhibit cell proliferation. {ECO:0000250|UniProtKB:P49715,
CC       ECO:0000250|UniProtKB:P53566, ECO:0000269|PubMed:8367486}.
CC   -!- FUNCTION: [Isoform 4]: Directly and specifically enhances ribosomal DNA
CC       transcription interacting with RNA polymerase I-specific cofactors and
CC       inducing histone acetylation. {ECO:0000250|UniProtKB:P49715}.
CC   -!- SUBUNIT: Binds DNA as a homodimer and as a heterodimer
CC       (PubMed:12578822, PubMed:1884998, PubMed:8367486). Can form stable
CC       heterodimers with CEBPB, CEBPD, CEBPE and CEBPG (PubMed:1377818,
CC       PubMed:1884998). Can form stable homodimers (also isoform 2 and isoform
CC       3 dimers) and heterodimers with CEBPB (with isoform 2 and isoform 3)
CC       and CEBPG (PubMed:1377818, PubMed:8367486). Interacts with PRDM16 (By
CC       similarity). Interacts with UBN1 (By similarity). Interacts with
CC       ZNF638; this interaction increases transcriptional activation (By
CC       similarity). Interacts with the complex TFDP2:E2F1; the interaction
CC       prevents CEBPA binding to target gene promoters and represses its
CC       transcriptional activity (By similarity). Interacts with RB1 (By
CC       similarity). Interacts (when phosphorylated at Ser-193) with CDK2,
CC       CDK4, E2F4 and SMARCA2 (By similarity). Interacts with SREBPF1 (By
CC       similarity). Interacts with FOXO1 (via the Fork-head domain); the
CC       interaction increases when FOXO1 is deacetylated (By similarity).
CC       Interacts with SIX1 (By similarity). Interacts (via recognition
CC       sequence) with TRIB1 (By similarity). {ECO:0000250|UniProtKB:P49715,
CC       ECO:0000250|UniProtKB:P53566, ECO:0000269|PubMed:12578822,
CC       ECO:0000269|PubMed:1377818, ECO:0000269|PubMed:1884998,
CC       ECO:0000269|PubMed:20075868, ECO:0000269|PubMed:8367486}.
CC   -!- SUBUNIT: [Isoform 1]: Interacts with TAF1A and UBTF.
CC       {ECO:0000269|PubMed:20075868}.
CC   -!- SUBUNIT: [Isoform 4]: Interacts with NPM1.
CC       {ECO:0000269|PubMed:20075868}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:8367486}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Nucleus, nucleolus
CC       {ECO:0000269|PubMed:20075868}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=4;
CC       Name=1;
CC         IsoId=P05554-1; Sequence=Displayed;
CC       Name=2; Synonyms=CEBPalpha-p42 {ECO:0000303|PubMed:8367486};
CC         IsoId=P05554-2; Sequence=VSP_057552;
CC       Name=3; Synonyms=C/EBPalpha-p30 {ECO:0000303|PubMed:8367486};
CC         IsoId=P05554-3; Sequence=VSP_057551;
CC       Name=4; Synonyms=extended-C/EBPalpha {ECO:0000303|PubMed:20075868};
CC         IsoId=P05554-4; Sequence=VSP_057609;
CC   -!- TISSUE SPECIFICITY: Isoform 2 and isoform 3 are expressed in liver (at
CC       protein level). {ECO:0000269|PubMed:8367486}.
CC   -!- DEVELOPMENTAL STAGE: Isoform 2 and isoform 3 are not expressed at 1 day
CC       before birth, relative concentration of both isoforms increases with
CC       the age of the animal, reaching maximal levels in the adulthood.
CC       {ECO:0000269|PubMed:8367486}.
CC   -!- DOMAIN: The recognition sequence (54-72) is required for interaction
CC       with TRIB1. {ECO:0000250|UniProtKB:P49715}.
CC   -!- PTM: Sumoylated, sumoylation blocks the inhibitory effect on cell
CC       proliferation by disrupting the interaction with SMARCA2.
CC       {ECO:0000269|PubMed:16735515}.
CC   -!- PTM: Phosphorylation at Ser-193 is required for interaction with CDK2,
CC       CDK4 and SWI/SNF complex leading to cell cycle inhibition.
CC       Dephosphorylated at Ser-193 by protein phosphatase 2A (PP2A) through
CC       PI3K/AKT signaling pathway regulation. Phosphorylation at Thr-222 and
CC       Thr-226 by GSK3 is constitutive in adipose tissue and lung. In liver,
CC       both Thr-222 and Thr-226 are phosphorylated only during feeding but not
CC       during fasting. Phosphorylation of the GSK3 consensus sites selectively
CC       decreases transactivation activity on IRE-controlled promoters.
CC       {ECO:0000250|UniProtKB:P53566}.
CC   -!- PTM: Ubiquitinated by COP1 upon interaction with TRIB1.
CC       {ECO:0000250|UniProtKB:P49715}.
CC   -!- MISCELLANEOUS: The V296A substitution has little effect on the binding
CC       of CEBPA to its consensus site (5'-GCAAT-3'), while greatly increasing
CC       affinity for cAMP response element (CRE) sites (5'-GTCAT-3').
CC       {ECO:0000269|PubMed:12578822}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Mutagenesis in position: 14: RRQR -> AAAA
CC       abolishes nucleolar localization and prevents induction of 45S pre-RNA.
CC       {ECO:0000269|PubMed:20075868}.
CC   -!- SIMILARITY: Belongs to the bZIP family. C/EBP subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X12752; CAA31242.1; -; Genomic_DNA.
DR   EMBL; AC109741; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   PIR; S06890; A54265.
DR   RefSeq; NP_001274506.1; NM_001287577.1. [P05554-4]
DR   RefSeq; NP_001274507.1; NM_001287578.1. [P05554-2]
DR   RefSeq; NP_001274508.1; NM_001287579.1. [P05554-3]
DR   RefSeq; NP_036656.1; NM_012524.3. [P05554-1]
DR   PDB; 1NWQ; X-ray; 2.80 A; A/C=281-340.
DR   PDBsum; 1NWQ; -.
DR   AlphaFoldDB; P05554; -.
DR   SMR; P05554; -.
DR   BioGRID; 246437; 148.
DR   ComplexPortal; CPX-60; bZIP transcription factor complex, Cebpa-Ddit3.
DR   ComplexPortal; CPX-64; bZIP transcription factor complex, Cebpa-Cebpa.
DR   DIP; DIP-28138N; -.
DR   IntAct; P05554; 5.
DR   STRING; 10116.ENSRNOP00000063123; -.
DR   iPTMnet; P05554; -.
DR   PhosphoSitePlus; P05554; -.
DR   PaxDb; 10116-ENSRNOP00000063123; -.
DR   GeneID; 24252; -.
DR   KEGG; rno:24252; -.
DR   UCSC; RGD:2326; rat. [P05554-1]
DR   AGR; RGD:2326; -.
DR   CTD; 1050; -.
DR   RGD; 2326; Cebpa.
DR   eggNOG; KOG3119; Eukaryota.
DR   HOGENOM; CLU_043327_2_0_1; -.
DR   InParanoid; P05554; -.
DR   OrthoDB; 2959124at2759; -.
DR   PhylomeDB; P05554; -.
DR   TreeFam; TF105008; -.
DR   Reactome; R-RNO-9616222; Transcriptional regulation of granulopoiesis.
DR   EvolutionaryTrace; P05554; -.
DR   PRO; PR:P05554; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:1990647; C:C/EBP complex; ISO:RGD.
DR   GO; GO:0036488; C:CHOP-C/EBP complex; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0016363; C:nuclear matrix; IDA:RGD.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:RGD.
DR   GO; GO:0035189; C:Rb-E2F complex; IDA:RGD.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; ISO:RGD.
DR   GO; GO:0005667; C:transcription regulator complex; IDA:RGD.
DR   GO; GO:0003682; F:chromatin binding; ISO:RGD.
DR   GO; GO:0031490; F:chromatin DNA binding; ISO:RGD.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; ISO:RGD.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:RGD.
DR   GO; GO:0071837; F:HMG box domain binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0019900; F:kinase binding; ISO:RGD.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:RGD.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:RGD.
DR   GO; GO:0001163; F:RNA polymerase I transcription regulatory region sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; ISO:RGD.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0097677; F:STAT family protein binding; ISO:RGD.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; ISO:RGD.
DR   GO; GO:0006953; P:acute-phase response; IEP:RGD.
DR   GO; GO:0031100; P:animal organ regeneration; IEP:RGD.
DR   GO; GO:0050873; P:brown fat cell differentiation; ISO:RGD.
DR   GO; GO:0030154; P:cell differentiation; IEP:RGD.
DR   GO; GO:0008283; P:cell population proliferation; ISO:RGD.
DR   GO; GO:0071285; P:cellular response to lithium ion; ISO:RGD.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; ISO:RGD.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; ISO:RGD.
DR   GO; GO:0071466; P:cellular response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0008203; P:cholesterol metabolic process; ISO:RGD.
DR   GO; GO:0006351; P:DNA-templated transcription; IEA:InterPro.
DR   GO; GO:0001892; P:embryonic placenta development; ISO:RGD.
DR   GO; GO:0097009; P:energy homeostasis; ISO:RGD.
DR   GO; GO:0002070; P:epithelial cell maturation; ISO:RGD.
DR   GO; GO:0045444; P:fat cell differentiation; IDA:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0030851; P:granulocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0071425; P:hematopoietic stem cell proliferation; ISO:RGD.
DR   GO; GO:0048839; P:inner ear development; ISO:RGD.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0055088; P:lipid homeostasis; ISS:UniProtKB.
DR   GO; GO:0001889; P:liver development; IEP:RGD.
DR   GO; GO:0030324; P:lung development; ISS:UniProtKB.
DR   GO; GO:0030225; P:macrophage differentiation; ISO:RGD.
DR   GO; GO:0007613; P:memory; IEP:RGD.
DR   GO; GO:0007005; P:mitochondrion organization; ISO:RGD.
DR   GO; GO:0030099; P:myeloid cell differentiation; ISO:RGD.
DR   GO; GO:0045786; P:negative regulation of cell cycle; ISO:RGD.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:1902034; P:negative regulation of hematopoietic stem cell proliferation; ISO:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:ComplexPortal.
DR   GO; GO:0007219; P:Notch signaling pathway; ISO:RGD.
DR   GO; GO:0002076; P:osteoblast development; IEP:RGD.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; IMP:RGD.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:RGD.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; ISO:RGD.
DR   GO; GO:0043032; P:positive regulation of macrophage activation; ISO:RGD.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; ISO:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0042127; P:regulation of cell population proliferation; ISO:RGD.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0071548; P:response to dexamethasone; IEP:RGD.
DR   GO; GO:0007584; P:response to nutrient; IEP:RGD.
DR   GO; GO:0080184; P:response to phenylpropanoid; IEP:RGD.
DR   GO; GO:0033274; P:response to vitamin B2; IEP:RGD.
DR   GO; GO:0006360; P:transcription by RNA polymerase I; ISS:UniProtKB.
DR   GO; GO:0000050; P:urea cycle; ISO:RGD.
DR   GO; GO:0050872; P:white fat cell differentiation; ISO:RGD.
DR   CDD; cd14711; bZIP_CEBPA; 1.
DR   Gene3D; 1.20.5.170; -; 1.
DR   InterPro; IPR004827; bZIP.
DR   InterPro; IPR046347; bZIP_sf.
DR   InterPro; IPR031106; C/EBP.
DR   InterPro; IPR016468; C/EBP_chordates.
DR   PANTHER; PTHR23334; CCAAT/ENHANCER BINDING PROTEIN; 1.
DR   PANTHER; PTHR23334:SF5; CCAAT_ENHANCER-BINDING PROTEIN ALPHA; 1.
DR   Pfam; PF07716; bZIP_2; 1.
DR   PIRSF; PIRSF005879; CCAAT/enhancer-binding; 1.
DR   SMART; SM00338; BRLZ; 1.
DR   SUPFAM; SSF57959; Leucine zipper domain; 1.
DR   PROSITE; PS50217; BZIP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative initiation;
KW   Developmental protein; Direct protein sequencing; DNA-binding;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Reference proteome;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..358
FT                   /note="CCAAT/enhancer-binding protein alpha"
FT                   /id="PRO_0000076615"
FT   DOMAIN          282..345
FT                   /note="bZIP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   DNA_BIND        285..300
FT                   /evidence="ECO:0000269|PubMed:12578822"
FT   REGION          1..70
FT                   /note="Required to repress E2F1:TFDP1-mediated
FT                   transcription, to inhibit cell cycle and to induce
FT                   adipocyte differentiation"
FT                   /evidence="ECO:0000269|PubMed:11672531"
FT   REGION          1..55
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          54..72
FT                   /note="Required for interaction with TRIB1"
FT                   /evidence="ECO:0000250|UniProtKB:P49715"
FT   REGION          126..200
FT                   /note="Required to induce adipocyte differentiation"
FT                   /evidence="ECO:0000269|PubMed:11672531"
FT   REGION          176..195
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          180..194
FT                   /note="Required to functionally cooperate with SREBF1 in
FT                   promoter activation"
FT                   /evidence="ECO:0000250|UniProtKB:P53566"
FT   REGION          213..310
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          240..358
FT                   /note="Interaction with FOXO1"
FT                   /evidence="ECO:0000250|UniProtKB:P53566"
FT   REGION          286..313
FT                   /note="Basic motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   REGION          317..345
FT                   /note="Leucine-zipper"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00978"
FT   COMPBIAS        36..50
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        177..194
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        218..238
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        277..309
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         159
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P49715"
FT   MOD_RES         193
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P53566"
FT   MOD_RES         222
FT                   /note="Phosphothreonine; by GSK3"
FT                   /evidence="ECO:0000250|UniProtKB:P53566"
FT   MOD_RES         226
FT                   /note="Phosphothreonine; by GSK3"
FT                   /evidence="ECO:0000250|UniProtKB:P53566"
FT   MOD_RES         230
FT                   /note="Phosphoserine; by GSK3"
FT                   /evidence="ECO:0000250|UniProtKB:P53566"
FT   CROSSLNK        159
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000269|PubMed:16735515"
FT   CROSSLNK        159
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P49715"
FT   VAR_SEQ         1..117
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000269|PubMed:8367486"
FT                   /id="VSP_057551"
FT   VAR_SEQ         1..14
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000269|PubMed:8367486"
FT                   /id="VSP_057552"
FT   VAR_SEQ         1
FT                   /note="M -> MRGRGRVGVLGGRRRQRRHAQAGGRRGSPCRENSNSPM (in
FT                   isoform 4)"
FT                   /id="VSP_057609"
FT   MUTAGEN         159
FT                   /note="K->A,R: Not sumoylated. No effect of sumoylation on
FT                   cell cycle inhibition."
FT                   /evidence="ECO:0000269|PubMed:16735515"
FT   MUTAGEN         285
FT                   /note="Y->A: Decreased transcription factor activity.
FT                   Strongly decreased transcription factor activity; when
FT                   associated with R-293."
FT                   /evidence="ECO:0000269|PubMed:12578822"
FT   MUTAGEN         285
FT                   /note="Y->A: Increases interaction with TFDP1 and TFDP2,
FT                   reduces DNA-binding, transactivation activity and represses
FT                   E2F1:TFDP1-mediated transcription, loss of cell cycle
FT                   inhibition and adipogenesis induction."
FT                   /evidence="ECO:0000269|PubMed:11672531,
FT                   ECO:0000269|PubMed:20176812"
FT   MUTAGEN         287
FT                   /note="V->A: No effect on repression of E2F1:TFDP1-mediated
FT                   transcription, no effect on cell cycle inhibition or
FT                   adipogenesis; when associated with A-290."
FT                   /evidence="ECO:0000269|PubMed:11672531"
FT   MUTAGEN         289
FT                   /note="R->A: Loss of DNA-binding and transcription factor
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:12578822"
FT   MUTAGEN         290
FT                   /note="E->A: No effect on repression of E2F1:TFDP1-mediated
FT                   transcription, no effect on cell cycle inhibition or
FT                   adipogenesis; when associated with A-287."
FT                   /evidence="ECO:0000269|PubMed:11672531"
FT   MUTAGEN         293
FT                   /note="N->R: Decreased transcription factor activity.
FT                   Strongly decreased transcription factor activity; when
FT                   associated with A-285."
FT                   /evidence="ECO:0000269|PubMed:12578822"
FT   MUTAGEN         294
FT                   /note="I->A: Increases interaction with TFDP1 and TFDP2,
FT                   reduces transactivation activity and represses E2F1:TFDP1-
FT                   mediated transcription, loss of cell cycle inhibition and
FT                   adipogenesis induction, no effect on DNA-binding; when
FT                   associated with A-297."
FT                   /evidence="ECO:0000269|PubMed:11672531,
FT                   ECO:0000269|PubMed:20176812"
FT   MUTAGEN         296
FT                   /note="V->A: No effect on DNA-binding and transcription
FT                   factor activity, but modified sequence specificity."
FT                   /evidence="ECO:0000269|PubMed:12578822"
FT   MUTAGEN         297
FT                   /note="R->A: Increases interaction with TFDP1 and TFDP2,
FT                   reduces transactivation activity and represses E2F1:TFDP1-
FT                   mediated transcription, loss of cell cycle inhibition and
FT                   adipogenesis induction, no effect on DNA-binding; when
FT                   associated with A-294."
FT                   /evidence="ECO:0000269|PubMed:11672531,
FT                   ECO:0000269|PubMed:20176812"
FT   MUTAGEN         299
FT                   /note="S->D: Isoform 4: Stimulates nucleolar retention of
FT                   isoform 4. No effect on interaction with NPM1, TAF1A and
FT                   UBTF."
FT                   /evidence="ECO:0000269|PubMed:20075868"
FT   MUTAGEN         301
FT                   /note="D->A: No effect neither on interaction with TFDP1 or
FT                   TFDP2 nor on transactivation activity or repression of
FT                   E2F1:TFDP1-mediated transcription, no effect on cell cycle
FT                   inhibition or adipogenesis; when associated with A-304."
FT                   /evidence="ECO:0000269|PubMed:11672531,
FT                   ECO:0000269|PubMed:20176812"
FT   MUTAGEN         304
FT                   /note="K->A: No effect neither on interaction with TFDP1 or
FT                   TFDP2 nor on transactivation activity or repression of
FT                   E2F1:TFDP1-mediated transcription, no effect on cell cycle
FT                   inhibition or adipogenesis; when associated with A-301."
FT                   /evidence="ECO:0000269|PubMed:11672531,
FT                   ECO:0000269|PubMed:20176812"
FT   HELIX           282..338
FT                   /evidence="ECO:0007829|PDB:1NWQ"
SQ   SEQUENCE   358 AA;  37371 MW;  4DA8F112F6EA95D0 CRC64;
     MESADFYEAE PRPPMSSHLQ SPPHAPSNAA FGFPRGAGPA PPPAPPAAPE PLGGICEHET
     SIDISAYIDP AAFNDEFLAD LFQHSRQQEK AKAAAGPAGG GGDFDYPGAP AGPGGAVMSA
     GAHGPPPGYG CAAAGYLDGR LEPLYERVGA PALRPLVIKQ EPREEDEAKQ LALAGLFPYQ
     PPPPPPPPHP HASPAHLAAP HLQFQIAHCG QTTMHLQPGH PTPPPTPVPS PHPAPAMGAA
     GLPGPGGSLK GLAGPHPDLR TGGGGGGGAG AGKAKKSVDK NSNEYRVRRE RNNIAVRKSR
     DKAKQRNVET QQKVLELTSD NDRLRKRVEQ LSRELDTLRG IFRQLPESSL VKAMGNCA
//
